| Code | CSB-RA850914MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to MK-0482, targeting LILRB4 (Leukocyte Immunoglobulin-Like Receptor B4), an inhibitory immune checkpoint receptor primarily expressed on myeloid cells including monocytes, macrophages, and dendritic cells. LILRB4 functions as a critical immune suppressor by delivering inhibitory signals upon ligand binding, dampening immune cell activation and effector functions. This receptor plays a significant role in tumor immune evasion, particularly in hematologic malignancies such as acute myeloid leukemia (AML) and monocytic leukemia, where it is frequently overexpressed on malignant cells and contributes to an immunosuppressive tumor microenvironment.
MK-0482, developed by Merck, represents a therapeutic antibody designed to block LILRB4-mediated immune suppression and restore anti-tumor immune responses. This biosimilar antibody serves as a valuable research tool for investigating LILRB4 biology, exploring immune checkpoint mechanisms in myeloid cells, and studying potential therapeutic strategies for hematologic cancers and other diseases characterized by aberrant myeloid cell function. It enables researchers to evaluate LILRB4 blockade effects in preclinical models and advance understanding of myeloid-mediated immune regulation.
There are currently no reviews for this product.